# PT-141

> Melanocortin-4 receptor agonist FDA-approved for HSDD in premenopausal women.

- Also known as: Bremelanotide, Vyleesi
- Class: Reproductive
- FDA approved: Yes
- Canonical page: https://www.americanpeptide.com/catalog/pt-141

## Overview

Bremelanotide (PT-141) is a cyclic heptapeptide melanocortin agonist with preferential activity at MC4R. Approved by the FDA in 2019 for hypoactive sexual desire disorder in premenopausal women.

PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin agonist with preferential activity at the MC4R receptor. It is a metabolite of Melanotan II, refined away from pigmentation toward central sexual-response pathways.

Unlike vascular treatments for sexual dysfunction, PT-141 acts in the central nervous system on the circuits that govern desire and arousal. It is FDA-approved (Vyleesi, 2019) for hypoactive sexual desire disorder (HSDD) in premenopausal women.

## Mechanism

MC4R-preferential melanocortin agonism in CNS sexual-response circuits.

## Chemistry

| Property | Value |
| --- | --- |
| Molecular formula | C50H68N14O10 |
| Molecular weight | 1025.2 Da |
| CAS number | 189691-06-3 |
| PubChem CID | [9941379](https://pubchem.ncbi.nlm.nih.gov/compound/9941379) |

## Research areas

Studied in: HSDD, CNS sexual response, Ischemia models.

Guides on this site:

- [Sexual & Reproductive Health](https://www.americanpeptide.com/research-areas/sexual-reproductive): Peptides studied across the HPG axis and CNS sexual-response pathways.

## Key research

- Central arousal mechanism — a cyclic α-MSH analog acting on melanocortin MC3R / MC4R in the hypothalamus to drive sexual desire independent of the reproductive hormone axis (Molinoff / Diamond et al., 2003).
- HSDD — FDA-approved (Vyleesi, 2019) for hypoactive sexual desire disorder in premenopausal women.
- Distinct from vascular agents — acts on central desire circuits rather than on blood flow.
- Compared to kisspeptin — PT-141 produces acute central arousal via melanocortin receptors, while kisspeptin acts upstream on the GnRH hormone axis; they address different research questions.
- FDA-approved (Vyleesi) — for a specific indication.

## FAQs

### What is PT-141?

PT-141 (bremelanotide) is a melanocortin MC4R agonist FDA-approved (Vyleesi) for hypoactive sexual desire disorder in premenopausal women.

### How does it differ from erectile-dysfunction medications?

Those act on blood flow; PT-141 acts centrally, on the brain circuits that govern sexual desire and arousal.

### How is it related to Melanotan II?

PT-141 is a metabolite of Melanotan II, refined toward MC4R and sexual-response activity and away from pigmentation.

### Is this medical advice?

No — this page is a research and educational reference, not medical advice.

## Latest research

Recent trials and publications mentioning PT-141, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily).

### Recent trials

- [1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder](https://clinicaltrials.gov/study/NCT02333071) — COMPLETED · PHASE3 · NCT02333071
- [2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder](https://clinicaltrials.gov/study/NCT02338960) — COMPLETED · PHASE3 · NCT02338960
- [Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder](https://clinicaltrials.gov/study/NCT01382719) — COMPLETED · PHASE2 · NCT01382719
- [Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)](https://clinicaltrials.gov/study/NCT00425256) — COMPLETED · PHASE2 · NCT00425256

---

Source: AmericanPeptide.com — https://www.americanpeptide.com/catalog/pt-141
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.